Accueil   Diary - News   All news Valneva Announces A New EB66® Cell Line Clinical Development License Agreement with GeoVax

Valneva Announces A New EB66® Cell Line Clinical Development License Agreement with GeoVax

European biotechnology company Valneva SE (Valneva) announced that it has signed a clinical development license agreement with the US firm GeoVax Labs, Inc. (OTCQB: GOVX), to develop MVAbased vaccines in Valneva’s EB66® vaccine production cell line.